EGFR and non-small cell lung carcinoma: Here CFM-4.16 or Sorafenib treatments cause a moderate increase in PARP cleavage as well as decline in levels of mitotic cyclin B1 in both the parental and EGFR TKI-resistant NSCLC cells.